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ABSTRACT

Background: The GI microbiome has not been characterized in dogs being medically
managed for congenital portosystemic shunts [CPSS].
Objectives: To characterize the fecal microbiome in a population of dogs being medically
managed for CPSS.
Animals: 27 client-owned dogs.
Methods: Prospective cohort study enrollment of fecal samples was performed with
follow-up data collected retrospectively. The overall fecal dysbiosis index [DI] and
individual bacterial abundances were determined using real-time qPCR. Medical
management, clinical findings, clinicopathologic, and outcome variables were collected,
and logistic regression analyses were performed to evaluate associations between these
variables and overall DI and bacterial abundances. Numerical variables were evaluated
with general linear models.
Results: All dogs were administered a therapeutic hepatic diet and lactulose, while
antibiotics were used in 22/27 (81.5%) dogs and acid suppressants in 7/27 (25.9%) dogs.
Seventeen dogs (63.0%) had a DI > 2. The median DI in this population was 3.02 (range,
4.23-8.42), and the median DI in dogs receiving and not receiving antibiotics was 4.3
(range, -4.23 – 8.42) and 1.52 (range, -1.62 – 5.43), respectively.
No significant association between any of the analyzed variables and the DI was
identified. The abundance of E. coli was positively significantly affected by the use of
metronidazole (p = 0.024).
Conclusions and clinical importance: Dysbiosis appears to be common in dogs that are
being medically managed for CPSS, though the clinical significance remains unclear.
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CHAPTER ONE

Introduction
The microbiota of the mammalian gastrointestinal (GI) tract consists of trillions of
organisms performing a variety of crucial roles both locally and systemically.1-3
Characterization of the GI microbiome has evolved from culture-based models to highthroughput DNA sequencing techniques or targeted quantitative polymerase chain
reaction (qPCR) assays, which have allowed for the characterization of the microbiome at
the genetic and species level in various species.3-5
Several studies have characterized bacterial populations for the GI flora in healthy
humans and animals.1-3 Subsequently, extensive research has been performed evaluating
the GI microbiome characteristics in human and canine populations with specific
pathologies such as chronic inflammatory enteropathies, diabetes, obesity, and
hepatopathy-induced hepatic encephalopathy (HE).6-10 By using the previously identified
healthy control profiles of intestinal microbiota in comparison to the profiles from the
diseased populations, the concept of a “dysbiosis index” (DI) was established, which
focuses the analysis of shifts in the microbiome to certain important bacterial groups.4
Certain alterations in the GI microbiome have been postulated to be a useful adjunct for
identifying disease states or a potential monitoring parameter for treatment efficacy.4-8,11
The role of the GI microbiome in chronic hepatopathies and HE has been frequently
investigated in humans, with ammonia being identified as a key player.10,12,13 Significant
differences have been reported in humans between the colonic microbiota of cirrhosis or
HE patients and healthy control individuals, and some suggest the microbiome alterations
in affected patients may contribute to more significant clinical signs of HE via alteration
of the intestinal barrier function, an increased proportion of urease-producing bacteria, or
in other ways.11-13,14 Therefore, it has been postulated that manipulation of the
microbiome may contribute to improved outcomes in these patients.
In dogs, the most common cause of HE is related to congenital portosystemic shunts
(CPSS).15 Single or multiple aberrant blood vessels allow portal venous blood to bypass
the liver parenchyma with CPSS.15,16 Medical management for dogs with PSS can
include a restricted protein diet and administration of lactulose, antibiotics,
anticonvulsants, or probiotics. Surgical attenuation of the CPSS is often recommended to
restore more normal portal blood flow and improve liver function. Some individual
components of medical management for CPSS have been investigated for effects on the
microbiome in dogs.4,15,17-21 Based on the literature, it is apparent that lactulose, diet, and
certain antibiotics have the potential to alter the microbiome; however, these studies
investigate effects in healthy dogs, people, or non-hepatic disease.11,15,16,17-20 Because
dogs being medically managed for CPSS are often prescribed these medications for long
periods, this may lead to long term dysbiosis and potential subsequent health
consequences.
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There is a deficit in the literature as to the effects of these medications on the fecal
microbiome and DI in dogs with CPSS and a complete lack of information as to whether
these effects have any consequences on the clinical signs or outcomes of dogs with
CPSS.
The aims of the current study were to characterize dysbiosis in dogs presenting with
CPSS and to evaluate for associations between dysbiosis and clinical variables such as
medical management, clinical signs, clinicopathologic findings, and postoperative
outcomes. We hypothesized that medical management for CPSS would have a significant
impact on the dysbiosis index, but that clinical outcome of the patient would not be
affected regardless of the level of dysbiosis.

Materials and Methods
Case selection:
Dogs presenting to the University of Tennessee College of Veterinary Medicine
(UTCVM) with a previous diagnosis of CPSS (confirmed either with transsplenic portal
scintigraphy or computed tomography) were prospectively recruited from June, 2018 to
August, 2019.
Inclusion criteria:
Dogs were included in the study following definitive diagnosis of CPSS using either
CT/angiography or transsplenic nuclear portal scintigraphy and if fecal samples were able
to be collected at the initial visit prior to surgical intervention for CPSS. All animals were
enrolled following informed owner consent in accordance with the protocol approved by
the University of Tennessee Institutional Animal Care and Use Committee (AUP #26410918). Animals were excluded if the fecal sample was not sufficient to be analyzed, if a
fecal sample was not obtained, or if a fecal sample was not obtained prior to
administration of perioperative antibiotics for the CPSS attenuation procedure.
Medical record review:
Information regarding patient signalment (breed size, sex, age, and reproductive status),
weight, clinical signs prior to medical management (GI signs, neurologic signs, urinary
signs), medications at the time of sample collection, clinical signs following initiation of
medical management, preoperative clinicopathologic findings (complete blood count
(CBC), serum biochemistry panel, pre- and post-prandial serum bile acids, and resting
plasma ammonia), type of surgical intervention, postoperative clinical outcome, and
postoperative albumin, BUN, cholesterol, and glucose values. Postoperative
clinicopathologic and outcome data was obtained via a combination of medical record
review and communication with referring veterinarians. Clinical management of the dogs
was not altered for the study parameters, and each dog was managed at the discretion of
the attending clinician, including adjustments to medical management perioperatively or
postoperatively and surgical attenuation. In general, each dog was recommended to have
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a follow-up serum biochemistry panel, CBC, and pre- and post-prandial serum bile acids
performed between 3-6 months postoperatively. Neurologic signs included seizures,
ataxia, head pressing, or mental obtundation. Gastrointestinal signs included vomiting,
diarrhea, or regurgitation, and were considered distinct from anorexia or hyporexia.
Lower urinary tract signs included hematuria, stranguria, or dysuria.
Closure of the CPSS following surgical intervention was suspected based on the
following findings in follow-up blood analyses: normalization or improvement of serum
bile acids22 with improvement or normalization of hepatic synthetic factors such as
albumin, glucose, cholesterol, or BUN.
Sample collection:
Fecal samples were either collected via free-catch fecal samples, digital rectal exam, or a
fecal loop, and stored in a cryogenic storage container. Following fecal collection, the
samples were immediately stored in a -80-degree Celsius freezer until all samples for
study inclusion were collected and shipped for analysis. Samples were then shipped on
dry ice and maintained in a -80 degree Celsius freezer at the Texas A&M Veterinary
Medical Diagnostic Laboratory until the molecular diagnostics were performed.
Fecal quantitative PCR analysis:
DNA was extracted from each fecal sample (100 mg) using the MoBio Power soil DNA
isolation kit (MoBio Laboratories, USA) according to the manufacturer’s instructions.
The qPCR assays were performed as previously reported by M.K. AlShawaqfeh, et al. In
summary, qPCR reactions were performed using SYBR green-based reaction mixtures.
The final total reaction volume was 10 µL. The final mix was composed of 5 µL SsoFast
EvaGreen supermix (Bio-Rad Laboratories, CA, USA), 0.4 µL each of a forward and
reverse primer, 2.6 µL of PCR water and 2 µL of normalized DNA. The PCR conditions
were as follows: initial denaturation at 98°C for 3s and annealing for 3s. Melt curve
analysis was performed post-amplification using these conditions: 95°C for 1 min, 55°C
for 1 min and increasing incremental steps of 0.5°C for 80 cycles for 5s each. All samples
were run in duplicate fashion. The qPCR data were expressed as the log amount of DNA
(fg) for each particular bacterial group/10 ng of isolated total DNA. Each fecal sample
was evaluated for the overall bacterial number, as well as the individual bacterial species
including: Universal Bacteria, Faecalibacterium, Turicibacter, Streptococcus, E. coli,
Blautia, Fusobacterium, and C. hiranonis. The overall dysbiosis index was then
calculated for each dog as previously described by AlShawaqfeh, et al.4
The reference ranges for the bacteria tested to determine if the abundance was normal or
abnormal were expressed as log DNA/gram of feces, and included Universal Bacteria
(10.6-11.4), Faecalibacterium (3.4-8.0), Turicibacter (4.6-8.1), Streptococcus (1.9-8.0),
E. coli (0.9-8.0), Blautia (9.5-11.0), Fusobacterium (7.0-10.3), and C. hiranonis (5.17.1).4 The DI was classified as normal DI (< 0), a moderate shift (0-2), or a significant
shift (> 2).
3

Statistical analysis:
Normality tests were conducted on numeric variables using Shapiro-Wilke tests.
Descriptive statistics were calculated. Normally distributed data are presented as a mean
± SD, and non-normally distributed data are expressed as median and range. Logistic
regression analysis was used to evaluate the effects of clinical variables (clinical signs,
medical management, clinicopathologic values, and outcome data) on the categorical
outcomes of bacterial abundance (normal or abnormal) and DI (normal, equivocal, or
dysbiosis). The effects of clinical variables on numeric outcomes (such as
clinicopathologic data) were evaluated using general linear models. Diagnostic analysis
was conducted to examine model assumptions for normality and equal variance using
Shapiro-Wilk test and Levene's test respectively. Ranked transformation was applied if
diagnostic analysis exhibited violation of normality and equal variance assumptions. Post
hoc multiple comparisons were performed with Tukey’s adjustment. Statistical
significance was identified at the level of 0.05. Analyses were conducted in SAS 9.4
TS1M7 for Windows 64x (SAS institute Inc., Cary, NC).

Results
A total of 27 dogs were included in the study in accordance with the inclusion criteria.
The study population included 17 (63.0%) male dogs and 10 (37.0%) female dogs. Ten
(58.8%) male dogs were neutered, and 6 (60%) female dogs were spayed. Median age at
the time of fecal collection was 10 months (range, 3-48). Median body weight at the time
of collection was 4.9 kg (range, 1.5-32.8).
Prior to initiation of medical management, documented clinical signs in the dogs of the
study included neurologic signs in 16/27 (59.3%), gastrointestinal signs in 13/27 (48.1%),
episodic or persistent anorexia or hyporexia in 11/27 (40.7%), and lower urinary tract
signs in 5/27 (18.5%).
At the time of fecal collection, medical management had been instituted previously for all
dogs. Medical management consisted of varying combinations of a therapeutic hepatic
diet (all dogs), lactulose (all dogs), antibiotics in 22/27 (81.5%), acid suppressants in 7/27
(25.9%), antiepileptics in 3/27 (11.1%), and probiotics in 2/27 (7.4%). The antibiotics
most commonly prescribed were metronidazole in 17 dogs receiving antibiotics (77.3%),
amoxicillin in six (27.3%), and one each of amoxicillin/clavulanic acid (Clavamox,
Zoetis, Parsippany-Troy Hills, NJ) and neomycin (4.5%). The median duration of
lactulose administration at the time of fecal collection was 50.5 days (range, 1-842). The
median duration of antibiotic administration was 45 days (range, 22-842).
Following initiation of medical management, the following clinical signs remained
present: four (14.8%) with hyporexia or anorexia, three (11.1%) with neurologic signs
(none with seizures), three (11.1%) with distinct GI signs, and three (11.1%) with lower
urinary tract signs. Only two dogs developed new clinical signs between the onset of
medical management and fecal collection - one with hyporexia/anorexia and one with
lower urinary tract signs.
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In total, 22/27 (81.5%) dogs underwent surgical intervention for attenuation of CPSS
including 14 (63.6%) with ameroid constrictor placement and eight (36.4%) with
percutaneous transvenous coil embolization. Follow-up data was available in 20 (90.9%)
dogs undergoing surgical intervention for the CPSS, and 13 (65.0%) had bloodwork
findings suggestive of closure of the PSS based on interpretation of serum bile acids and
hepatic synthetic factors.
Information pertaining to blood analyses performed during the same hospitalization for
fecal collection can be found in Table 1. The bacterial abundance as measured in these
dogs is available in Table 2. In total, 17/27 (63.0%) dogs in the study had a DI of > 2,
which has previously been reported as the cutoff for dysbiosis in dogs.4 The overall
median DI in this population of dogs was 3.02 (range 4.23-8.42). The median DI in dogs
receiving antibiotics was 4.3 (range -4.23 – 8.42), and the median DI in dogs not
receiving antibiotics was 1.52 (range -1.62 – 5.43) (p = 0.58).
No significant effect on the DI from any of the components of medical management was
noted. However, the abundance of E. coli was significantly positively affected by the use
of metronidazole (p = 0.024). No significant effects on the DI or any individual bacterial
species abundances were identified with amoxicillin, amoxicillin/clavulanic acid, or
neomycin. Preoperative serum albumin had a significant negative impact on the DI (p =
0.009), whereas no other clinicopathologic variables had a significant relationship. C.
hiranonis abundances were significantly positively affected by preoperative serum
albumin (p = 0.035), serum GGT (p = 0.04), and serum cholesterol (p = 0.023). E. coli
abundances were significantly negatively affected by increasing preoperative platelet
count (p = 0.04), lymphocytes (p = 0.049), and BUN (p = 0.016).

Discussion
The current study is the first in the veterinary literature to describe evaluation of the
dysbiosis index in a cohort of dogs diagnosed with CPSS. Given the fact that many dogs
with CPSS are administered medications to mitigate the clinical signs secondary to CPSS
and that these medications are known to affect overall dysbiosis, evaluating these
interactions is important to further understand treatment effects on these patients.4,15,18-20
The overall rate of dysbiosis (DI >2) in the study population was relatively high at
63.0%, but no significant associations were identified between the DI and any individual
component of medical management or clinical signs. Additionally, there was no
significant association between the DI and clinical outcome or any of the
clinicopathologic findings apart from a negative association with preoperative albumin.
Additionally, significant associations between certain parameters and the abundance of
individual bacterial species were also identified.
The role of the human GI microbiome in chronic hepatopathies and HE is well
established.10,21 Significant differences have been shown in the colonic microbiota of
human patients with cirrhosis or HE and healthy control individuals, and some authors
5

Table 1. Blood analytes. Summarized data for clinicopathologic variables for the study population.
Post-operatively, only synthetic hepatic factors and serum bile acids were analyzed. Numerical values for
post-operative serum bile acids were not recorded, but rather if there was an improvement or not as
compared to the preoperative values. All reference ranges are those used for the University of Tennessee
College of Veterinary Medicine, aside from resting ammonia.42
Abbreviations: BUN, blood urea nitrogen; ALT, alanine aminotransferase; ALP, alkaline phosphatase;
GGT, gamma-glutamyl transferase; PCV, packed cell volume

Blood
Analyte

Number of
cases tested
at
presentation
Serum Biochemistry
Albumin
26
(g/dL)
Globulins
26
(g/dL)
Cholesterol
25
(mg/dL)
BUN
27
(mg/dL)
Glucose
27
(mg/dL)
ALT (IU/L)
26
ALP (IU/L)

26

GGT (IU/L) 26
Total
26
bilirubin
(mg/dL)
Complete Blood Count
PCV (%)
27
Total Protein
(g/dL)
White blood
cells
(x10E3/uL)
Neutrophils
(x10E3/uL)
Lymphocytes
(x10E3/uL)

26
26

26
26

Median
(range)

Number of
Median
cases tested
(range)
postoperatively

2.5 (1.8-3.6) 19
3.45 (1.54.8)
178 (64420)
5 (2-13)

N/A

107 (51121)
82.5 (31516)
111 (41441)
3 (2-13)
0.4 (0.1-0.7)

19

14
19

3.0 (2.44.1)
N/A

Reference
Range

3.0-4.3
2.6-4.7

229.5
74-255
(174-290)
8.5 (4-26) 18-40
87-179

N/A

88 (80195)
N/A

N/A

N/A

12-79

N/A
N/A

N/A
N/A

0-5
0.1-0.7

36.1 (28.050.5)
5.95 (3.37.3)
13.6 (9.520.0)

N/A

N/A

34-48

N/A

N/A

6.6-8.4

N/A

N/A

4.7-15.3

9.2 (3.817.8)
9.5 (1.1915.8)

N/A

N/A

2.00-9.20

N/A

N/A

1.05-8.00
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29-109

Table 1 continued
Platelets
26
(x10E3/uL)
Liver Function Tests
Pre-prandial 22
Bile Acids
(µg/dL)
Post23
Prandial Bile
Acids
(µg/dL)
Resting
13
Ammonia
(µmol/L)

196.5 (103395)

N/A

N/A

169-480

182.2 (0318.8)

18

N/A

0-30

209.1 (69382.3)

18

N/A

0-10

140 (66-864.4)

N/A

N/A

<70
µmol/L42

Table 2. Bacterial abundance. Summary of the various bacterial abundances present in the study
population. Reference intervals were established in 120 healthy dogs. 4

Bacteria

Universal
Bacteria
Faecalibacterium

Abundance
Reference
Interval (log
DNA/gram feces)

Median (range)

Number of
Dogs Outside
Reference
Interval (%)

10.6-11.4

10.9 (10.4313.22)
7.28 (3.457.32)
7.46 (3.259.13)
6.05 (2.14-8.2)
8.15 (0.888.77)
11.23 (6.0412.25)
9.69 (6.5111.63)
3.07 (0.016.84)

6 (22.2%)

Number of
Dogs
Within
Reference
Interval (%)
21 (77.8%)

2 (7.4%)

25 (92.6%)

7 (25.9%)

20 (74.1%)

1 (3.7%)
6 (22.2%)

26 (96.3%)
21 (77.8%)

14 (51.9%)

13 (48.1%)

8 (29.6%)

19 (70.4%)

19 (70.4%)

8 (29.6%)

3.4-8.0

Turicibacter

4.6-8.1

Streptococcus
E. coli

1.9-8.0
0.9-8.0

Blautia

9.5-11.0

Fusobacterium

7.0-10.3

C. hiranonis

5.1-7.1
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suggest that the alterations in the microbiome in these patients may contribute to more
significant clinical signs of HE or complications leading to mortality.12,21 Investigation of
the GI microbiome in dogs with hepatic pathology is more limited. A pilot study in 2015
conducted with 10 dogs revealed that one dog with chronic active hepatitis had
Fusobacteria as the dominant bacterial phylum in the distal gut, as opposed to healthy
dogs or dogs with distinct systemic pathology not involving the liver, in which the
dominant organisms were Firmicutes or Proteobacteria, though clinical significance of
this finding could not be determined.23 Given the sparsity of literature, the role of
dysbiosis in relation to hepatic dysfunction or pathology, including CPSS, in dogs has yet
to be elucidated.
All dogs in the present study had been medically managed prior to fecal sample
collection with medications to reduce ammonia production and absorption in the gut and
the manifestation of correlated clinical signs. All dogs were fed a therapeutic hepatic diet
at the time of fecal collection. Moderately protein-restricted diets that provide highquality protein (bioavailable and with a balanced amino acid composition) are
recommended for dogs with CPSS, as these diets have been shown to reduce the severity
of HE scores in dogs with CPSS. 15,16,24 Though several studies on the effects of diet on
intestinal microbiota in dogs have been published, none have been performed specifically
with a reduced protein diet fed to dogs with hepatic pathology.24-27 These studies show
that diet has the potential to cause statistically significant shifts in the fecal microbiota
with variable size effect, corroborating the results of several human studies investigating
the effects of diet on the microbiome.28-30 Given the other treatments administered in the
dogs of this study, it is difficult to determine how significant the effects of the
administered therapeutic hepatic diets were on the fecal microbiota of these dogs.
Lactulose was also administered to all dogs in the present study prior to fecal collection.
Lactulose has been shown to cause a significant, reversible alteration of the microbiome
in healthy dogs, but its effects on the microbiome have not been studied in dogs with any
disease state.15 Additionally, the effects of lactulose administered concurrently with
antibiotics has not been studied in dogs. Contrary to the aforementioned study in dogs,
one study in humans showed that lactulose did not have a significant impact on the
microbiome in patients with cirrhosis.31 Because all dogs in the present study were being
treated with lactulose at the time of fecal sample collection, we cannot draw conclusions
about the specific effect of lactulose in this population, though it may have contributed to
the relatively high prevalence of dysbiosis (63.0%) in light of the previous canine study.
This is an area that would benefit from potential future study.
No significant differences in the DI were noted between the 22 dogs (81.5%) receiving
antibiotics and the five (18.5%) that were not. Previous studies performed in humans and
dogs have shown both transient and long-lasting dysbiosis associated with antibiotic use,
including the highly prevalent problem of Clostridium difficile in people.18,32-34 Despite
the lack of association with the DI, the present study identified a significant association
between metronidazole and a greater abundance of E. coli (p = 0.024), in agreement with
8

the results of a previous study investigating the use of metronidazole in healthy dogs.18
No significant correlation between the use of other antibiotics was identified in this study,
though sample sizes were limited. The relationship between amoxicillin/clavulanic acid
and the DI has previously been investigated in dogs, and no significant affect was
shown.35
Clostridium hiranonis has garnered attention in its role in intestinal health, as well as the
conversion of bile acids in the gut. This bacterial species has a strong negative correlation
with an increase in the dysbiosis index in dogs.4 In our study, C. hiranonis was below the
canine reference range in 19 (70.4%) dogs, with a median value of 0.99. Our study
population also exhibited significantly elevated pre- (median: 112.9, range 10.5-318.8)
and post-prandial (median: 205.6, range 69-382.3) serum bile acid concentrations,
consistent with what is typical for dogs with CPSS. The shunting of blood bypassing the
normal hepatic recycling of bile acids in these dogs with CPSS is likely the main driving
force behind this elevation in bile acids, but the prevalence of low abundances of C.
hiranonis may play a role as well.
The abundance of C. hiranonis was also significantly positively correlated with
preoperative serum albumin and cholesterol. While these findings may be incidental, they
may also be associated with subclinical malabsorptive GI disease. It is the authors’
observation that many dogs with CPSS are suspected to have concurrent GI disease at the
time of presentation, in addition to reference of this concurrent process in a group of dogs
with intrahepatic CPSS.37 Several studies have elucidated the correlation between
inflammatory enteropathies and dysbiosis in dogs, and the above findings may support
this association.5-7,38 Further study is required to determine the individual role of fecal C.
hiranonis in dogs with CPSS prior to medical management.
We identified a significant negative correlation between the abundance of E. coli and
both pre-operative lymphocyte and platelet counts. Several studies in human medicine
have investigated a link between the GI microbiome, macronutrient environment, and
various immune cells, including B lymphocytes present in the gut-associated lymphoid
tissue (GALT).39,40 Platelets, in addition to their role in primary hemostasis, have also
been shown to be capable of immune defense against E. coli, while conversely the
lipopolysaccharide associated with E. coli has been shown to be lethal to platelets.41,42
Though these relationships have only been studied in humans, the negative correlation
identified in our study between E. coli abundance and platelet counts may be the result of
these effects. Further study focused on E. coli abundance and platelet and lymphocyte
counts would be required to confirm this correlation in dogs.
In our study, no significant correlation was identified between the DI and the
manifestation of clinical signs, either before or after medical management was initiated.
This may be the case for several reasons; the clinical signs in dogs with CPSS may be
more attributable to the shunting of blood bypassing the liver, increased production and
absorption of ammonia, or alterations to the GI blood supply as opposed to intestinal
9

dysbiosis. Additionally, our characterization of the microbiome was limited to fecal
samples. Fecal samples have been shown to be significantly different from small
intestinal samples, and the bacterial populations exhibit significant differences even
within individual dogs in transit from the stomach to the colon.36 It may be the case that
changes in the small intestinal microbiome are more clinically significant than those in
the colon or the feces for dogs with CPSS. Finally, there are many protective mechanisms
in place to prevent dysbiosis from cultivating clinical signs. These mechanisms include
the intimate association between the intestines and the immune system, as well as the
normal intestinal mucus layer that is present in healthy dogs and likely dogs with CPSS
(as opposed to dogs suffering from chronic inflammatory enteropathies).39,40 If these
protective functions were intact in the dogs in our study population, this may have also
contributed to the lack of significant association with the DI and the clinical signs listed.
Interpretation of the microbiome in our study was performed with 16s rRNA qPCR, as
determined by previous studies investigating the DI in dogs.4 This methodology is
intended to look at the “functional core” of the microbiome in dogs, which is well
preserved across differing individual dogs, dog breeds, and even between dogs and
humans.3 Hence, changes in other bacterial taxa or species not included in this
“functional core” may not have been identified in this population. Despite this potential
limitation, we elected to utilize the qPCR as a way of avoiding overinterpretation of
changes in the microbiome that may not be clinically relevant.
Our study had several limitations. The sample size of 27 dogs is relatively small,
increasing the likelihood for type II error for our statistical analyses, though it is the only
study to-date to specifically evaluate the fecal microbiota in dogs with CPSS. Though
fecal sample collection was performed prospectively, data collection on outcome was
performed retrospectively, and interpretation of clinical signs was often based on owner
observations or referring veterinarian medical records. Because medical management
administration was performed at home, owner compliance was likely variable, and
medical management strategies were diverse to start with as many referring veterinarians
elected different protocols when initiating treatment for suspected CPSS. Unfortunately,
there may be ethical implications to denying patients diagnosed with CPSS medical
management to improve or mitigate clinical signs and side effects related to their
diagnosis for study purposes.
In summary, our study is the first to describe the GI microbiome in dogs with CPSS. We
identified that dysbiosis is common in dogs being medically managed for CPSS, despite
some variability in the protocol being used. We did not observe a relationship between
fecal dysbiosis and clinical signs or outcome in dogs diagnosed with CPSS. Areas of
future study should include characterization of the microbiome and DI in dogs prior to
the initiation of medical management, and isolating individual components of the medical
management protocol with control groups to determine their individual contribution to
the changes described here. These studies will need to be performed in such a way to
avoid negative effects to patients which may require certain medications to maximize the
10

likelihood of an uncomplicated clinical course following CPSS diagnosis. The DI and
microbiome should also be described in dogs after having undergone surgical attenuation
of their CPSS and following cessation of medical management. Though the DI did not
appear to have any obvious effect on clinical outcomes in our study, controlled,
prospective studies are warranted to further investigate this relationship as this may hold
relevance for the treatment plan for dogs with CPSS.
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CHAPTER TWO
LITERATURE REVIEW
What is the normal canine GI flora/microbiota?
The microbiota of the mammalian gastrointestinal (GI) tract consists of trillions of
bacterial organisms performing a variety of crucial roles both locally and systemically.1-3
Characterization of the GI microbiome has evolved from culture-based models to highthroughput DNA sequencing techniques, which have allowed for the characterization of
the microbiome on the genetic and species level in various species, including canines.3-5
The canine GI microbiota consists of a massive array of bacterial species in addition to
archaea, fungi, protozoa, and viruses. In total, the estimated intestinal microbial load
ranges between 1012 and 1014 organisms which equates to roughly 10 times the
population of host cells.6 In comparing the canine microbiome to the human GI
microbiome, a “functional core” has been established that appears to result in a similar
functional capacity despite considerable inter- and intraspecies differences in the GI
microbial population.3 This has important implications for physiologic function in the
host, including polysaccharide degradation, synthesis of short-chain fatty acids, amino
acids, and vitamins, immune regulation, nutrient metabolism, and other physiological
processes.3,6-8
In general, in the dog, the bacterial concentrations in the GI tract increase in an aborad
direction beginning at the stomach. Typical bacterial counts in the stomach of the dog
range from 101 to 106 cfu/g.9 Bacterial counts in the duodenum tend in general to be low
(<103 cfu/g in duodenal aspirates), though considerable variation has been documented
between dogs, whereas the ileum, in general, exhibits higher bacterial counts closer to 107
cfu/g.6,10 In the small intestine of cats and dogs, the dominant bacterial groups to have
been cultured are Bacteroides, Clostridium, Lactobacillus, Bifidobacterium, and
Enterobacteriaceae, though more recent molecular characterization techniques have
revealed a larger diversity of bacterial species than previously recognized.6,11 Bacterial
counts in the colon of dogs have been documented between 109 and 1011 cfu/g, with
Firmicutes, Bacteroides, and Fusobacteria the predominant phyla.11 Considerable
investigation of the other components of the microbiome has also been performed, but is
outside the scope of this project.
How is the microbiome evaluated in an individual dog?
Given the diversity and immense number of bacteria present in the canine microbiome,
the techniques for determining the contributing organisms, and their relative abundance,
have evolved over time. Each technique inherently comes with a unique set of benefits
and drawbacks, which may impact their utility in research settings as opposed to clinical
applications. In general, evaluation of the fecal microbiome (as compared to colonic,
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small intestinal, gastric, etc.) is logistically the easiest and least invasive. Earlier
techniques for fecal microbiome evaluation were culture-based, and initially aided in
determining the most abundant taxa present in the microbiome of healthy dogs and cats:
Bacteroides, Clostridium, Lactobacillus, Bifidobacterium spp., and
Enterobacteriaciae.9,11,12 Bacterial cultures are performed both aerobically and
anaerobically, though anaerobic species are inherently more fastidious to grow in culture.
Distinct bacterial species were previously identified based on “colonial and cellular
morphologies, gram reactions, spore formation and anaerobic growth,” though more
recently genomic sequencing has made this process more streamlined. The bacterial
count per gram of feces can be calculated based on growth in various culture media,
though this may lead to underestimation of the true bacterial burden depending on the
ease of growth in culture.9 Proposed benefits of culture-based methods include the ability
to identify an active infection and the ability to perform concurrent antibiotic sensitivity
testing in a clinical setting.13
Culture-based microbiome analysis also has significant limitations. Because many of the
bacterial species in the microbiome are anaerobic, growth in culture may be challenging
or impossible, potentially leading to an underrepresentation of either bacterial diversity or
estimations of abundance.11,13 Additionally, performing bacterial cultures can be
laborious and time consuming, which may be a significant disadvantage when applied in
a clinical setting.
Subsequent studies sought to characterize the microbiome on a genomic level. Multiple
studies in dogs have evaluated the bacteria of the microbiome based on sequencing of 16s
ribosomal RNA (rRNA) genes utilizing polymerase chain reaction (PCR). Based on the
genomic sequences that are generated (so-called “shotgun sequencing”), operational
taxonomic units (OTUs) are determined, which aid in assigning these sequences to a
specific bacterial taxon.13,14 In doing so, the aim is to evaluate the bacterial diversity of
the microbiome in cats and dogs by identifying nearly all species that are present and
eliminating the need for organisms to be amenable to culture. These assays are not
necessarily targeted to individual bacterial taxa, but rather would often employ “universal
bacterial primers” during the PCR process.15 Though these assays are able to identify
many more bacterial species, there are still limitations to identification, particularly at the
species and strain level, and thus the true bacterial diversity or abundance may still be
underrepresented.16
With knowledge of the specific 16s rRNA sequences in these bacterial species, targeted
PCR primers can be used to identify and quantify bacterial species of particular interest,
such as those that exhibit abundance differences in healthy as compared to diseased
canine microbiomes. After identification of many of the bacterial species in the canine
microbiome and using their respective primers as part of PCR, it was possible to evaluate
differences in these populations between control dogs and those with various systemic
pathologies, including conditions such as inflammatory enteropathies.4 By isolating the
investigation of the microbiome to certain species, much of the “noise” is filtered out.
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Given that the coinciding changes in bacterial populations for a specific disease process
can be identified, this may lead to more clinical utility than culture-based methods or
shotgun sequencing. For example, the concept of the dysbiosis index was developed after
recognition that certain groups of bacteria were repeatably significantly different in dogs
with chronic enteropathies as compared to healthy control dogs.4,16 This index has been
standardized and differences can be directly evaluated between dogs.4,16
Results of these analyses are currently likely of more use in a research setting to evaluate
bacterial diversity in the microbiome, but their clinical application is limited given the
lack of implicit functional significance associated with each bacterial species, and the fact
that normal protective mechanisms (such as the mucosal mucus layer present in normal
intestine) may prevent changes in the microbiome composition from leading to pathology
or clinical signs.16 The study of “metabolomics” is an emerging field, and seeks to clarify
the function of the microbiome, as well as its contributions to various disease processes.
Importantly, even significant alterations in the microbiome may not manifest as clinically
identifiable disease states because of the presence of these protective mechanisms present
in healthy canine intestinal tracts. Thus, it is clear that evaluation of the microbiome and
its potential ramifications in a clinical setting should involve a multifaceted approach that
evaluates not only the microbiota, but also the relevant metabolic pathways, gene
expression, and interactions with the host.16 This combined approach likely represents the
bridge between laboratory research and clinical application of interpretation of
microbiome shifts.
What disease processes have been shown to change canine GI microbiota?
Coinciding with a better understanding of the composition of the GI microbiome in
healthy mammals, extensive research has been performed evaluating the GI microbiome
characteristics in human and canine populations with various pathologies. Disease
models evaluated in canines and humans include but are not limited to chronic
inflammatory enteropathies, diabetes, obesity, and hepatopathies leading to hepatic
encephalopathy (HE).15,17-21 By using the previously identified control profiles of
intestinal microbiota in comparison to the profiles from the diseased populations, the
concept of a “dysbiosis index” was established. This has been postulated to be a useful
adjunct for identifying disease states, or as a potential monitoring target for treatment
efficacy.4,5,15,17,18,21
What findings have been reported regarding hepatopathies and microbiota?
The role of the GI microbiome in chronic hepatopathies and hepatic encephalopathy (HE)
has been investigated in humans.21,23,24 Ammonia has been considered as one of the
primary causative agents of HE and is produced primarily from the process of urea
breakdown by urease producing large intestinal bacteria, as well as in the kidneys and
small intestine.21,23,24 Significant differences have been shown in the microbiota of the
colon between human patients with cirrhosis and/or HE and healthy control individuals,
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and some suggest that the alterations in the microbiome in these patients may contribute
to more significant clinical signs of HE or complications leading to mortality.23,25,26
Specifically, dysbiosis has been shown to have an important role in late-stage cirrhosis in
humans including intestinal bacterial overgrowth, small bowel dysmotility, increased gut
permeability, and decreased immunological defenses, all of which can predispose the
affected individual to bacterial translocation from the gut to the systemic circulation.26
This may also lead to septic bacterial peritonitis in human patients. The most commonly
isolated bacteria in these cases is E. coli, which has also been shown to be one of the
main bacteria increased in dysbiosis of dogs.4,26 Multifactorial immune suppression has
been identified as an underlying cause for these bacterial infections, related to decreased
activity of bactericidal phagocytic cells.27,28
Intestinal dysbiosis has also been linked specifically with HE in humans, in which the
prevalence of certain bacteria is increased, resulting in metabolic effects that contribute to
HE.29 Reported bacteria associated with HE in humans with cirrhosis include E. coli,
Staphylococcus spp., Streptococcaceae, and Veillonellaceae.30,31
Investigation of the GI microbiome in canines with hepatic pathology is more limited. A
pilot study in 2015 conducted with 10 dogs revealed that one dog with chronic active
hepatitis exhibited Fusobacteria as the dominant bacterial phyla in the distal gut, as
opposed to healthy dogs or dogs with distinct systemic pathology not involving the liver,
in which the dominant organisms were Firmicutes or Proteobacteria, though clinical
significance could not be determined.32 Given the sparsity of literature, the role of
dysbiosis in relation to hepatic dysfunction or pathology in dogs has yet to be elucidated.
What effects does lactulose have in the GI tract? Does it change the microbiota?
In dogs, the most common cause of HE is related to congenital portosystemic shunts
(CPSS) due to the high prevalence of this disease.33 Congenital portosystemic shunts are
defined as one or more aberrant blood vessels that allow portal venous blood to bypass
the liver parenchyma. This leads to neurologic clinical signs such as ataxia, lethargy,
head pressing, or seizures.34 Typical medical management of dogs with PSS includes a
restricted protein diet, lactulose administration, potential administration of antibiotics,
anticonvulsant medications, or probiotics, all of which are intended to reduce ammonia
production and absorption.35,36 Additionally, dogs with intrahepatic portosystemic shunts
are at an increased risk for gastric or duodenal ulceration, and current recommendations
for therapy include proton pump inhibitors both in the short and long terms.35 Provided
these patients are deemed healthy enough to undergo general anesthesia, surgical
attenuation of the CPSS is often recommended in order to restore more normal portal
blood flow and liver function in the long term. Except for anticonvulsants, the effects that
the individual components of medical management for CPSS have on the microbiome
have been investigated individually in dogs.22,37-39
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Lactulose is a synthetic disaccharide, an osmotic cathartic, and an ammonia reducer.
Osmotic cathartics result in water being retained or attracted into the intestinal lumen,
and may also cause enhanced mucosal secretion of fluid. Because no endogenous enzyme
exists to digest lactulose, it passes through the small intestine undigested.40 In the colon,
lactulose interacts with flora that break down saccharides, resulting in the production of
lactic, acetic, and other organic acids that decrease luminal pH. In patients with HE, this
effect is desirable as acidification of the fecal contents enhances the production of ionized
ammonium, which is nonabsorbable, as opposed to ammonia.40
The effect of lactulose on the GI microbiota has been studied in humans, mice, pigs, and
in healthy dogs, with effects ranging from negligible to dramatic.41-44 In one study of 18
healthy dogs, lactulose administration resulted in a decrease in bacterial diversity,
characterized by significant increases in Firmicutes and Actinobacteria, and a decrease in
Bacteroidetes and Fusobacteria.41 The authors posited that the increased presence of the
family Veillonellaceae, members of which convert lactate to acetate and butyrate, may be
beneficial as acetate has been negatively associated with proinflammatory cytokines in
cirrhosis, and butyrate has been shown to be protective against HE in humans.45 These
changes in the GI microbiota were found to be reversible with the cessation of lactulose
administration in this population of dogs.41 The effects of lactulose on the fecal
microbiota in dogs with hepatopathies and/or HE remains to be studied.
What effects does diet have on canine GI microbiota?
Dietary modification is another important component of medical management for dogs
with CPSS and/or HE. In general, restricted protein diets are recommended for dogs with
CPSS; the goal of a restricted protein diet is to reduce the production and absorption of
ammonia in the large intestine; this is accomplished, at least in part, by limiting the
substrate (i.e. protein) available to produce ammonia.36 Restricted protein diets with
varying sources of protein have been shown to reduce the severity of HE scores in dogs
with CPSS, and soy-based restricted protein diets may also lower the plasma ammonia
concentration.46
The nearly endless array of dietary effects on the GI microbiota that have been
investigated in humans are beyond the scope of this project. In dogs, several studies have
been published investigating the effects of diet on the intestinal microbiota, though none
have been performed specifically with a protein restricted diet.47-49 As discussed, the role
of the canine GI microbiota in hepatopathies, or more specifically CPSS/HE, has yet to
be elucidated, though extrapolation from studies in humans is compelling for a
meaningful relationship between the two.
As different diets lead to altered presence of nutrients and degradation products in the
intestinal tract, it stands to reason that there would be an impact on the GI microbiota
which have been shown to be closely involved in nutrient processing and absorption. In
healthy beagle dogs that were fed cellobiose, dose-dependent significant increases in
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Lactobacillaceae, Alloprevotella, Bacteroides, and Prevotella were observed.47 The fecal
pH in that study was unaffected by the dietary change, though the authors hypothesized
that the increased fecal lactate concentration in the study may have acidified the colonic
lumen (as opposed to the feces itself), which could be clinically relevant to dogs with
CPSS/HE. Additionally, this theoretical change in colonic luminal pH may have been
related to (or responsible for) the change in colonic microbiota.47 Fat content of the diet
showed no significant impact on fecal bacterial richness or diversity in one study, though
there were minor, statistically significant changes in individual bacterial taxa.48 Another
study investigating the impact of a raw meat diet as compared to a commercial diet found
that GI microbiota diversity was improved in the raw diet group, and that diet had a
significant impact on the end products of fermentation (e.g. lactic acid, acetate,
butyrate).49 Yet another study investigating a “bones and raw food” (BARF) diet showed
no significant increase in microbiota diversity, but did show an increase in prevalence of
E. coli and C. perfringens.50 It is apparent from these various studies that changes in the
nutrient profile in the gut can have significant effects on the microbiome, and that the
macronutrient composition of distinct diets can differ quite dramatically.
There is currently no literature detailing the effects of a restricted protein diet on the
canine GI microbiota, but these other dietary studies, as well as those documented in
human medicine, make it seem possible or even likely that such a relationship exists.
What effects do antibiotics have on canine GI microbiota?
As agents that inhibit bacterial growth or survival, antibiotics inherently have effects on
the GI microbiota that have been documented in numerous species, including humans and
canines. In humans, the alteration to the GI microbiota associated with antibiotic use may
be so significant as to predispose to pathologic colonization of the GI tract with
Clostridium difficile, which has been documented following use of several classes of
antibiotics including cephalosporins, clindamycin, and fluoroquinolones.51,52 The risk for
dysbiosis appears to last for several weeks after antibiotic exposure. A review article
published in 2017 details the multitude of effects of various antibiotics on the human GI
microbiome.53 The use of broad-spectrum antimicrobials has been shown to decimate
microbiome diversity, and in some cases may even precede long-lasting states of
dysbiosis that may predispose individuals to the development or exacerbation of other
disease processes. For more information on the individual profiles of effects of specific
antimicrobials on the human microbiome or individual bacterial taxa, the reader is
referred to this review article.53
In human patients with HE, antibiotic therapy is often a key component of preventing or
reducing the presence of clinical signs.54 The underlying rationale for antibiotic therapy
in these patients is the reduction in production and absorption of gut-derived neurotoxins,
as well as minimizing endotoxemia and inflammation. The most commonly used
antibiotics in these patients are neomycin, metronidazole, vancomycin, and rifaximin,
with rifaximin being most efficacious.54,55 An altered fecal microbiome in humans with
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cirrhosis has also been linked directly to changes in cognition.56 Several studies have
elucidated the role of rifaximin in altering the microbiome, and indicate that it may
actually have eubiotic properties as opposed to other antibiotics that cause or exacerbate
dysbiosis; the authors posit that this may be due to targeted effects on pathogenic bacteria
or indirect effects on the host, such as inhibition of bacterial attachment or reduction of
mucosal inflammation.57,58 Part of rifaximin’s eubiotic effects are its promotion of growth
of beneficial bacteria such as Bifidobacteria and Lactobacilli, even in patients with
gastrointestinal or liver disease.58
Oral antibiotic therapy has classically been a component of medical management of dogs
with CPSS and/or HE for the same reasons as listed above in humans, with metronidazole
being among the most commonly used. Though the veterinary literature on changes in the
GI microbiome is less robust, studies have examined antibiotic effects on GI flora in
healthy dogs with multiple types of antibiotics. One such study on the effects of
metronidazole found that there were significant decreases in fecal microbiome richness
and in certain key bacteria such as Fusobacteria, and these changes were still in place
four weeks after discontinuation of therapy.59 Other changes to the intestinal microbiota,
such as those seen with antibiotic responsive diarrhea, are less well understood.14 The
concept of metabolomics describes the translation of these alterations in bacterial
populations into their functional capacity; until this can be investigated further in
veterinary medicine, it will remain challenging to know the true relationship between the
GI microbiome and various disease processes with which it has been linked.
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